Re: Interesting Trades / Volume .....
in response to
by
posted on
Jan 26, 2019 10:54PM
, CD,
With upcoming top line results or full date release we could see a CVR deal with milestone payments that would protect both buyer and seller in the event that the FDA does not give full NDA acceptance . With good results and no safety issues Apabetalone could be a standard of care drug a major blockbuster, i would think a lot of BP would want to scoop RVX quickly IMO